Candel Therapeutics Inc (CADL) Stock Price, Quote & News

Company Profile

Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, develops immunotherapies for the cancer patients. It develops CAN-2409, which is in Phase III clinical trials for the treatment of prostate cancer; Phase II clinical trials for the treatment of pancreatic cancer; and Phase II clinical trials for the treatment of non-small cell lung cancer (NSCLC). The company is also developing CAN-3110, which is in Phase Ib clinical trials for the treatment of recurrent high-grade glioma. In...

Industry: Biotechnology

Sector: Healthcare

Phone: 617 916 5445

Website: www.candeltx.com

Address:

117 Kendrick Street, Suite 450, Needham, United States

claybridge Mar. 15 at 7:36 PM

$CADL I'm McLovin' it!

0 · Reply

stu4 Mar. 15 at 7:21 PM

$CADL Trump, has them too…now they are going off to a war, he said wouldn’t exist under him, but would under Kamala , hahahah ..is his kids going to…OH NO.

0 · Reply

stu4 Mar. 15 at 7:20 PM

$CADL one more time , Sam 🎹🎵🎹🎶🎵🎹🎶f For the gallaxtilly STUPID ..TAK MINIONS

0 · Reply

stu4 Mar. 15 at 7:18 PM

$CADL ahhh did Heap blow up your pumped balloon !! He spoke the truth

0 · Reply

stu4 Mar. 15 at 7:17 PM

$CADL More hype …the results of a trial aren’t even seen yet , hahaha Poor results sends TAK PACKING…as it did at Kintai !!!! He’ll, Omega therapeutics, him as a director went BANKRUPT

0 · Reply

SylviaLukowski688 Mar. 15 at 4:44 PM

Keeping $CADL on the watchlist and observing the chart.

0 · Reply

Spywest Mar. 15 at 3:48 PM

$CADL Keep stacking the dips

0 · Reply

claybridge Mar. 15 at 3:25 PM

$CADL Another one bites the dust!

0 · Reply

Heap_Of_Funk Mar. 15 at 2:53 PM

$CADL wrong about what? Tak is a bad ceo im not wrong. He should have sold or partnered up right after results. Instead he continues to make horrible financial deals over and over again. Stock price is five and sinking. Am I wrong?

0 · Reply

Greyhound9 Mar. 15 at 12:54 PM

$CADL I have blocked this person; these people are just trying to provoke you.

1 · Reply

Candel Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Recent Corporate Highlights

Mar 9, 2026, 8:05 AM EDT - 6 days ago

Candel Therapeutics To Present New Data after Extended Follow Up from Randomized Phase 3 Trial of Aglatimagene Besadenovec in Localized Prostate Cancer at the American Urological Association 2026 Annual Meeting

Mar 2, 2026, 4:05 PM EST - 12 days ago

Candel Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Feb 24, 2026, 8:05 AM EST - 19 days ago

Candel Therapeutics to Present at TD Cowen's 46th Annual Health Care Conference in Boston

Feb 20, 2026, 4:57 AM EST - 23 days ago

Stock Market Today: Dow Jones, S&P 500 Futures Rise Ahead Of Q4 GDP Numbers—Grail, Candel Therapeutics, Copart In Focus

CPRT IVV SPXL SPY SSO UPRO VOO

Feb 19, 2026, 9:40 PM EST - 23 days ago

Candel Therapeutics Announces Pricing of Public Offering

Feb 19, 2026, 4:05 PM EST - 23 days ago

Candel Therapeutics Announces Proposed $100 Million Public Offering

Feb 19, 2026, 4:01 PM EST - 23 days ago

Candel Therapeutics Announces $100M Royalty Funding Agreement with RTW to Support the Potential Launch of Aglatimagene Besadenovec (CAN-2409) in Localized Prostate Cancer

Feb 11, 2026, 8:05 AM EST - 4 weeks ago

Candel Therapeutics to Present at the 7th Annual Glioblastoma Drug Development Summit

Nov 17, 2025, 4:05 PM EST - 4 months ago

Candel Therapeutics to Host Virtual R&D Event on December 5, 2025

Nov 13, 2025, 8:25 AM EST - 4 months ago

Candel Therapeutics Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights

TRIN

Nov 4, 2025, 9:00 AM EST - 4 months ago

Candel Therapeutics Showcases Immunotherapy Leadership at SITC 2025, Demonstrating Integration of Clinical Innovation, Multi-Omics, and Artificial Intelligence to Advance Next-Generation Immunotherapies in Solid Tumors

Nov 3, 2025, 8:05 AM EST - 4 months ago

Candel Therapeutics to Present at Jefferies Global Healthcare Conference in London

Oct 16, 2025, 8:05 AM EDT - 5 months ago

Candel Therapeutics Appoints Leading Systems Immunology Expert Bali Pulendran, Ph.D., to Research Advisory Board

Oct 14, 2025, 8:10 AM EDT - 5 months ago

Candel Therapeutics Enters into $130 Million Term Loan Facility with Trinity Capital Inc.

Oct 14, 2025, 8:10 AM EDT - 5 months ago

Trinity Capital Inc. Provides $130 Million in Growth Capital to Candel Therapeutics, Supporting Development of Viral Immunotherapies to Fight Cancer

TRIN

Oct 14, 2025, 8:05 AM EDT - 5 months ago

Candel Therapeutics Announces Positive Interim Data After Repeated Administration of CAN-3110 in Recurrent Glioblastoma and Announces Publication in Science Translational Medicine

Oct 13, 2025, 10:22 AM EDT - 5 months ago

Candel Therapeutics Has A Protracted, But Real, Timeline To Approval Now

Oct 3, 2025, 9:05 AM EDT - 5 months ago

Candel Therapeutics to Present at the SITC 2025 Annual Meeting

Sep 29, 2025, 8:05 AM EDT - 5 months ago

Candel Therapeutics Presents Phase 3 Clinical Trial of CAN-2409 in Localized Prostate Cancer at ASTRO 2025

Sep 17, 2025, 8:05 AM EDT - 6 months ago

Candel Therapeutics to Present Phase 3 Results of CAN-2409 in Localized Prostate Cancer at ASTRO 2025

Sep 7, 2025, 10:53 AM EDT - 6 months ago

Candel Therapeutics: Potentially The Next Exciting Oncology Story

Sep 5, 2025, 12:47 PM EDT - 6 months ago

Candel Therapeutics: Oncolytic Immunotherapy Showing Broad Efficacy In Tough Tumors

Sep 2, 2025, 8:05 AM EDT - 6 months ago

Candel Therapeutics Appoints Renowned Immunotherapy Pioneer Carl H. June, M.D.

Aug 28, 2025, 8:05 AM EDT - 7 months ago

Candel Therapeutics to Participate in Upcoming Investor Conferences in September

Aug 14, 2025, 8:05 AM EDT - 7 months ago

Candel Therapeutics Reports Second Quarter 2025 Financial Results and Recent Corporate Highlights

Jul 30, 2025, 8:05 AM EDT - 8 months ago

Candel Therapeutics to Present at the Canaccord Genuity 45th Annual Growth Conference

Jul 24, 2025, 8:05 AM EDT - 8 months ago

Candel Therapeutics Receives EMA Orphan Designation for CAN-2409 for the Treatment of Pancreatic Cancer

Jul 9, 2025, 8:05 AM EDT - 8 months ago

Candel Therapeutics Expands Russell Index Presence with Addition to Multiple Value-Oriented Indexes in 2025 Reconstitution

Jun 24, 2025, 9:05 AM EDT - 9 months ago

Candel Therapeutics Announces $15 million Registered Direct Offering of Common Stock

Jun 23, 2025, 8:05 AM EDT - 9 months ago

Candel Therapeutics Appoints Charles Schoch as Chief Financial Officer

Jun 6, 2025, 8:05 AM EDT - 10 months ago

Candel Therapeutics Appoints Maha Radhakrishnan, M.D., to its Board of Directors

May 28, 2025, 8:05 AM EDT - 10 months ago

Candel Therapeutics Receives FDA Regenerative Medicine Advanced Therapy Designation for CAN-2409 for the Treatment of Prostate Cancer

May 27, 2025, 8:05 AM EDT - 10 months ago

Candel Therapeutics to Host Investor Conference Call Featuring Expert Clinical Perspectives on CAN-2409 Phase 3 Prostate Cancer Data Following 2025 ASCO Presentation

May 22, 2025, 5:05 PM EDT - 10 months ago

Candel Therapeutics Presents Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025

May 13, 2025, 8:05 AM EDT - 10 months ago

Candel Therapeutics Reports First Quarter 2025 Financial Results and Recent Corporate Highlights

May 6, 2025, 8:05 AM EDT - 11 months ago

Candel Therapeutics to Present at Upcoming Investor Conferences

Apr 23, 2025, 4:05 PM EDT - 11 months ago

Candel Therapeutics Announces Oral Presentation of Positive Phase 3 CAN-2409 Results in Localized Prostate Cancer at ASCO 2025

Apr 1, 2025, 8:01 AM EDT - 1 year ago

Candel Therapeutics Announces Publication of Phase 1b Clinical Trial Data on the Combination of CAN-2409 and Nivolumab plus Standard of Care in Newly Diagnosed High-Grade Glioma Patients

Mar 26, 2025, 4:05 PM EDT - 1 year ago

Candel Therapeutics Reports Both Prolonged Median Overall Survival and Long Tail of Survival in Phase 2a Clinical Trial of CAN-2409 in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment

Mar 20, 2025, 8:00 AM EDT - 1 year ago

Candel Therapeutics and IDEA Pharma Announce Strategic Partnership to Advance Path-to-Market Commercialization Efforts for CAN-2409

Mar 18, 2025, 8:00 AM EDT - 1 year ago

Candel Therapeutics Appoints Renowned Pancreatic Cancer Expert, Elizabeth M. Jaffee, M.D.

Mar 13, 2025, 4:15 PM EDT - 1 year ago

Candel Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Recent Corporate Highlights

Feb 25, 2025, 4:52 PM EST - 1 year ago

Candel Therapeutics: I Say Stay The Course Despite The Market's Rebuke Of Positive Pancreatic Data

Feb 25, 2025, 8:00 AM EST - 1 year ago

Candel Therapeutics Announces Positive Final Survival Data from Randomized Controlled Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer

Feb 20, 2025, 10:45 AM EST - 1 year ago

Candel Therapeutics: Entering Its Pivotal Year

Jan 13, 2025, 8:00 AM EST - 1 year ago

Candel Therapeutics Provides Corporate Update and Highlights Strong Pipeline Momentum and Key Value Drivers for 2025

Jan 2, 2025, 11:46 PM EST - 1 year ago

Best-Performing Stocks Of 2024

APP BYRN DAVE INOD JANX LUNR MSTR

Dec 16, 2024, 4:01 PM EST - 1 year ago

Candel Therapeutics Announces Closing of Public Offering and Full Exercise of the Underwriters' Option to Purchase Additional Shares

Dec 13, 2024, 8:53 AM EST - 1 year ago

Candel Therapeutics, 8x8 And Other Big Stocks Moving Lower In Friday's Pre-Market Session

EGHT

claybridge Mar. 15 at 7:36 PM

$CADL I'm McLovin' it!

0 · Reply

stu4 Mar. 15 at 7:21 PM

$CADL Trump, has them too…now they are going off to a war, he said wouldn’t exist under him, but would under Kamala , hahahah ..is his kids going to…OH NO.

0 · Reply

stu4 Mar. 15 at 7:20 PM

$CADL one more time , Sam 🎹🎵🎹🎶🎵🎹🎶f For the gallaxtilly STUPID ..TAK MINIONS

0 · Reply

stu4 Mar. 15 at 7:18 PM

$CADL ahhh did Heap blow up your pumped balloon !! He spoke the truth

0 · Reply

stu4 Mar. 15 at 7:17 PM

$CADL More hype …the results of a trial aren’t even seen yet , hahaha Poor results sends TAK PACKING…as it did at Kintai !!!! He’ll, Omega therapeutics, him as a director went BANKRUPT

0 · Reply

SylviaLukowski688 Mar. 15 at 4:44 PM

Keeping $CADL on the watchlist and observing the chart.

0 · Reply

Spywest Mar. 15 at 3:48 PM

$CADL Keep stacking the dips

0 · Reply

claybridge Mar. 15 at 3:25 PM

$CADL Another one bites the dust!

0 · Reply

Heap_Of_Funk Mar. 15 at 2:53 PM

0 · Reply

Greyhound9 Mar. 15 at 12:54 PM

$CADL I have blocked this person; these people are just trying to provoke you.

1 · Reply

stu4 Mar. 15 at 12:49 PM

$CADL NEW !!! therapy discovered in Spain for : Pancreatic Cancer …by world renown scientists. Guess whose name is missing …oh you all know !!!! I give you all a 100 on this quiz !!!! Imagine ….discovered and already in the works !!! Sorry , professor Higgins , singing and phonetics isn’t the way to hype your science ..A**Hole

1 · Reply

stu4 Mar. 15 at 12:12 PM

$CADL Usually , once approved , Wall Street looks for then “ earnings potential “ and TAK being a professor with no business acumen, will falter just like TRUMP, a BLOW HARD. Big Pharma will then be his competition and will suffocate his abilities to produce sales . Then ..the stock will languish, just like CHRS , which Fidelity owned until 2020 , ( as they own a small piece of this junk) and GOT THE FCUK OUT. And the bears will once again laugh all the way to the bank , as did I with 50% profit in 10 months ..Feb 2025-Jan 2026 Shall we all repeat this again , clearly we will !!! Apologize for being right ? , or are you at $25 from February 2025 , hahaha

1 · Reply

User123321 Mar. 15 at 8:13 AM

$CADL weren’t you here last week talking about all the cash they had? How long have you invested here?

1 · Reply

Heap_Of_Funk Mar. 15 at 3:58 AM

$CADL get it approved we will talk. Untill then its all a big nothing burger and only time can change that

1 · Reply

RaphaelRapoport Mar. 15 at 1:22 AM

$CADL When a drug becomes FDA approved what happens to all the bear bashers? Do they apologize or just disappear?

1 · Reply

VictoriaCapital Mar. 14 at 11:15 PM

$CADL Dr Tak is a key strategic leader in the industry. We are in good hands.

2 · Reply

Clemente4141 Mar. 14 at 5:50 PM

$CADL My take on shelving pancreatic trial for now… thinking Phase II NSCLC numbers must be good, otherwise they would be foolish to shelve pancreatic. I know there are other monetary issues too, but at least this is a silver lining possibly.

3 · Reply

Heap_Of_Funk Mar. 14 at 5:23 PM

$CADL you forgot to mention value creation hinges on good management Something cadl lacks. Great data, poor management 🤷‍♀️

0 · Reply

Heap_Of_Funk Mar. 14 at 4:47 PM

$CADL Tak has no idea what a catalyst is. He has spent the past 2 years on autopilot Shareholders want activism not passivism

0 · Reply

Heroforest Mar. 14 at 4:21 PM

$CADL the more you see these type of articles the closer we are. 9 months of wait for BLA, another 6 for thr approval. Let’s get through the finish line.

2 · Reply

PatSoonDiggler Mar. 14 at 1:24 PM

$CADL Will the FDA allow a regulatory filing based on the existing data? Could CADL move toward approval for CAN-2409 (Prostate) without another large Phase 3 trial? Discuss. I believe the FDA will not require further trials. That will dramatically shorten the timeline and lower the cash burn. Where are all these Bearish posts coming from?

4 · Reply

Xanderzzzzzzz Mar. 14 at 12:32 PM

$CADL A terrific time convening #Biotech and #Pharma leaders for a fantastic dinner and sunset cocktails over the Miami harbor last night. #MiamiCEO

1 · Reply

Market Cap	256.37M
Revenue (ttm)	0.00
Net Income (ttm)	-55.18M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.06

Volume	1,362,400
Avg Vol	1,077,522
Day's Range	N/A - N/A
Shares Out	54.90M
Stochastic %K	3%
Beta	-0.91
Analysts	Strong Sell
Price Target	$18.62